About Us
CTCELLS is a cutting-edge cancer diagnostics and drug development company, founded on the premise that effective cancer treatment requires tailored solutions for each individual.
Leveraging Circulating Tumor Cell (CTC) liquid biopsy technology, CTCELLS leads the industry with its unique automation capabilities, enabling the isolation of all types of circulating tumor cells.
With a strong focus on developing innovative cancer treatments, CTCELLS is dedicated to improving patient outcomes by matching cancer characteristics with the most suitable therapies, setting its sights on bringing hope to patients facing challenging cancer types. Join us in our mission to transform the landscape of cancer treatment.
Our Mission
Our mission at CTCELLS is to redefine cancer care by leveraging the unique insights provided by Circulating Tumor Cells (CTCs). Utilizing our state-of-the-art TRACE and RACE technologies, we focus on capturing and analyzing these vital biomarkers to equip researchers and clinicians with unparalleled diagnostic precision. Our dedication to advancing CTC analysis ensures that we provide robust, actionable data that drives personalized treatment strategies and enhances patient outcomes.
Our Vision
Our vision at CTCELLS is to lead the charge in early cancer detection and tailored treatment strategies through the advanced analysis of Circulating Tumor Cells. By pioneering the use of innovative liquid biopsy techniques, we aim to detect cancer at its earliest, most treatable stages and to optimize treatment efficacy based on detailed CTC profiles. We are committed to transforming cancer treatment paradigms, contributing to a future where cancer can be effectively managed or eradicated.
Our Values
Converging Precise Diagnostics To Personalized Therapeutics
TRACE & PATRIOT
TRACE: True Real-time Answer with CTC Evaluation
PATRIOT: Precisely, Attack the Tumor Regions with Immune Technology Of Tomorrow
Meet the Team
-
Minseok Kim Ph.D
FOUNDER & CEO
-
Jungmin Lee Ph.D
CEO
-
Seil Jang Ph.D
CTO
-
Hyun Young Shin
COO
